<DOC>
	<DOCNO>NCT00568633</DOCNO>
	<brief_summary>Acute myeloid leukemia ( AML ) cancer bone marrow mostly affect old adult . Even best chemotherapy , two-year disease-free survival achieve minority patient . Bone marrow transplantation sibling donor may improve cure rate ; however , patient 50 year age high risk complication therefore generally exclude treatment option . Recently group develop transplantation strategy old cancer patient protect transplant-associated complication , yet interfere ability transplant donor cell destroy cancer cell . With new method , safely evaluate transplantation curative therapy AML patient age 50 . We assemble clinical scientific researcher throughout state California study compare bone marrow transplantation use new approach best standard care chemotherapy AML patient age 50 . The result study potential establish new treatment standard improve survival old AML patient .</brief_summary>
	<brief_title>Allogeneic HCT Using Nonmyeloablative Host Conditioning With TLI &amp; ATG v SOC AML</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<mesh_term>Antilymphocyte Serum</mesh_term>
	<criteria>Both gender individual ethnic group eligible . 1 . Patients great equal 50 year age less equal 75 year age . 2 . Patients de novo AML base FAB WHO criteria . 3 . Patients intermediate unfavorable cytogenetic abnormality base SWOG Cytogenetic Criteria . 4 . Patients achieve 1st morphologic CR , CRp ( complete remission low platelet ) follow one two course induction therapy . ( See definition CR page 6 . ) CR must document 8 week prior date enrollment . 5 . Patients fit nonmyeloablative transplantation best treatment . 6 . Patients able understand willing sign write informed consent document . 1 . Patients AML favorable cytogenetic feature base SWOG Cytogenetic Criteria . 2 . Patients Complete Remission time enrollment . 3 . Patients treatmentrelated MDSrelated AML . 4 . CR document &gt; 8 week prior date enrollment . 5 . Patients active CNS disease identify positive CSF cytospin time enrollment . 6 . Patients prior concurrent malignancy except localized nonmelanoma skin malignancy treat cervical carcinoma situ . Cancer treat curative intent &lt; 5 year previously allow . Cancer treat curative intent &gt; 5 year previously allow . Patients low grade lymphomas eligible long require active treatment control disease . 7 . Patients plan allogeneic transplant use fulldose conditioning , irrespective knowledge donor status . 8 . Patients whose life expectancy severely limited ( &lt; 1 year ) diseases malignancy . 9 . Karnofsky Performance Score &lt; 60 . 10 . Patients pregnant breastfeeding . 11 . Patients HIV seropositive . 12 . Patients uncontrolled infection ( presume document ) progression appropriate therapy great one month . 13 . Patients symptomatic coronary artery disease , uncontrolled congestive heart failure . Left Ventricular Ejection Fraction require measure , however measure , patient exclude ejection fraction &lt; 30 % . 14 . Patients require supplementary continuous oxygen . DLCO require measure , however measure , patient exclude DLCO &lt; 35 % . 15 . Patients clinical laboratory evidence liver disease evaluate cause liver disease , clinical severity term liver function histology , degree portal hypertension . Patients follow liver function abnormality exclude : 1 . Fulminant liver failure . 2 . Cirrhosis evidence portal hypertension bridge fibrosis . 3 . Alcoholic hepatitis . 4 . Esophageal varix . 5 . A history bleed esophageal varix . 6 . Hepatic encephalopathy . 7 . Uncorrectable hepatic synthetic dysfunction evidence prolongation prothrombin time . 8 . Ascites related portal hypertension . 9 . Chronic viral hepatitis total serum bilirubin &gt; 3 mg/dL . 10 . Symptomatic biliary disease .</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2013</verification_date>
</DOC>